Author information:
(1)Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
Toronto, ON, Canada. Electronic address: karen.yee@uhn.ca.
(2)Institute of Hematology "L. and A. Seràgnoli", University Hospital S. 
Orsola-Malpighi, Bologna, Italy.
(3)Department of Hematology, Aix-Marseille University, Institut Paoli-Calmettes, 
Marseille, France.
(4)Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne 
Hospital, and Sir Peter MacCallum Department of Oncology, University of 
Melbourne, Melbourne, VIC, Australia.
(5)Division of Hematology, Keck School of Medicine of the University of Southern 
California, Los Angeles, CA, United States.
(6)Division of Hematologic Oncology, Segal Cancer Centre, Jewish General 
Hospital, Montreal, QC, Canada.
(7)Department of Medical Oncology, Thomas Jefferson University, Philadelphia, 
PA, United States.
(8)Department of Medicine, Division of Oncology, New York Medical College, 
Valhalla, NY, United States.
(9)Department of Haemato-Oncology, Beatson West of Scotland Cancer Centre, 
Glasgow, UK.
(10)Division of Hematology/Medical Oncology, Department of Internal Medicine, 
Seoul National University Hospital, Seoul, Republic of Korea.
(11)Department of Hematology, Asan Medical Center, Seoul, Republic of Korea.
(12)Translational Medicine-Oncology, Roche Innovation Center, New York, NY, 
United States.
(13)Clinical Pharmacology, Roche Innovation Center, New York, NY, United States.
(14)Clinical Pharmacology, F. Hoffmann-La Roche, Basel, Switzerland.
(15)Product Development Oncology, Genentech, Inc, South San Francisco, CA, 
United States.
(16)Department of Biostatistics Oncology, F. Hoffmann-La Roche, Basel, 
Switzerland.
(17)Clinical Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland.
(18)Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), 
IRCCS, Meldola, Italy.